Drugs / RTX-224
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05219578 | Jan → Nov 2022 | cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma +1 | Rubius Therapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTX-224 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219578 ↗ |
| Route | Intravenous | “administered intravenously on Day 1 of each cycle.” NCT05219578 ↗ |